ClearPoint Neuro, Inc. CLPT
Medical/Dental Instruments · data as of November 13, 2026
ClearPoint Neuro, Inc. (CLPT) is a healthcare company listed in the US with a market value of about $272M. In the twelve months to September 30, 2026 it had revenue of $45M and net income of -$36M, a net margin of -79.4%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 24% a year, a 5-year average ROIC of -34%.
About ClearPoint Neuro
ClearPoint Neuro is listed in the US and classified in medical/dental instruments. Revenue went from $4M in 2014 to $37M in 2025, growth of about 23.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 17% over three years (dilution for shareholders). It spends 38% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45M | $37M | $31M | $24M | $21M | $16M | $13M | $11M | $7M | $7M | $6M |
| Net income | -$36M | -$26M | -$19M | -$22M | -$16M | -$14M | -$7M | -$6M | -$6M | -$7M | -$8M |
| Free cash flow | -$48M | -$24M | -$9M | -$14M | -$16M | -$13M | -$8M | -$3M | -$5M | -$6M | -$6M |
| EPS (diluted) | $-1.21 | $-0.90 | $-0.70 | $-0.90 | $-0.68 | $-0.69 | $-0.43 | $-0.42 | $-0.56 | $-0.93 | $-2.93 |
| Net margin | -79.4% | -69.1% | -60.2% | -92.2% | -80.0% | -88.4% | -52.9% | -49.4% | -83.8% | -97.1% | -140.4% |
| ROIC | — | -22.1% | -53.8% | -50.5% | -26.4% | -17.3% | -18.5% | -51.5% | -83.1% | -46.6% | -158.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $21.50, 154% above the current price; targets range from $18.00 to $25.00; the consensus rating is “none”; expected EPS is $-1.17 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does ClearPoint Neuro pay a dividend?
Not currently.
Is ClearPoint Neuro a good stock to buy?
We do not give buy or sell advice. ClearPoint Neuro scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.